May 23rd 2025
A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.
Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy